Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus (Q24236456)

7

0 references

Bianca Hemmingsen

1

object named as

Bianca Hemmingsen

0 references

Thomas Almdal

5

object named as

Thomas Almdal

0 references

Christina Hemmingsen

6

object named as

Christina Hemmingsen

0 references

author name string

Søren S Lund

2

0 references

Allan Vaag

Cochrane Database of Systematic Reviews

4

0 references

publication date

15 June 2011

0 references

published in

0 references

cites work

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The effects of intensive glycaemic control on body composition in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Evaluation of a pharmaceutical care model on diabetes management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intravenous insulin administration on left ventricular performance during non-ST-elevation acute coronary events in patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The Minnesota diabetes complications clinical trial the first three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Treatment intensification in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Comparison of three protocols for tight glycemic control in cardiac surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of Moderate Intensity Glycemic Control After Cardiac Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Randomised controlled trial of structured personal care of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The response to short-term intensive insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Clinical inertia in general practice: widespread and related to the outcome of diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Resurrections in Toronto: the emergence of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The barrier of hypoglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Uncertainty method improved on best-worst case analysis in a binary meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Sequential methods for random-effects meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

On the measurement of happiness. An examination of the Bradburn scale in the Canada Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Insulin treatment and cardiovascular disease; friend or foe? A point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Overcoming the limitations of current meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Rosiglitazone for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Meta-analysis of rare and adverse event data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Insiders criticise FDA's decision not to withdraw rosiglitazone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Is intensive glycemic control worth the expense?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008143.PUB2

7 January 2021

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

Retinopathy Progression in Type 2 Diabetes

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

Standards of medical care in diabetes--2008.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

Pioglitazone for type 2 diabetes mellitus

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

Standards of medical care in diabetes--2010.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD008143.PUB2

10.1002/14651858.CD008143.PUB2

9 February 2024

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4690119

OpenCitations bibliographic resource ID

4690119

1 reference